BibTex format
@article{Innes:2021:10.3389/fcimb.2021.684659,
author = {Innes, AJ and Mullish, BH and Ghani, R and Szydlo, RM and Apperley, JF and Olavarria, E and Palanicawandar, R and Kanfer, EJ and Milojkovic, D and McDonald, JAK and Brannigan, ET and Thursz, MR and Williams, HRT and Davies, FJ and Marchesi, JR and Pavl, J},
doi = {10.3389/fcimb.2021.684659},
journal = {Frontiers in Cellular and Infection Microbiology},
title = {Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation},
url = {http://dx.doi.org/10.3389/fcimb.2021.684659},
volume = {11},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:p>The gut microbiome can be adversely affected by chemotherapy and antibiotics prior to hematopoietic cell transplantation (HCT). This affects graft success and increases susceptibility to multidrug-resistant organism (MDRO) colonization and infection. We performed an initial retrospective analysis of our use of fecal microbiota transplantation (FMT) from healthy donors as therapy for MDRO-colonized patients with hematological malignancy. FMT was performed on eight MDRO-colonized patients pre-HCT (FMT-MDRO group), and outcomes compared with 11 MDRO colonized HCT patients from the same period. At 12 months, survival was significantly higher in the FMT-MDRO group (70% <jats:italic>versus</jats:italic> 36% <jats:italic>p</jats:italic> = 0.044). Post-HCT, fewer FMT-MDRO patients required intensive care (0% <jats:italic>versus</jats:italic> 46%, <jats:italic>P</jats:italic> = 0.045) or experienced fever (0.29 <jats:italic>versus</jats:italic> 0.11 days, <jats:italic>P</jats:italic> = 0.027). Intestinal MDRO decolonization occurred in 25% of FMT-MDRO patients <jats:italic>versus</jats:italic> 11% non-FMT MDRO patients. Despite the significant differences and statistically comparable patient/transplant characteristics, as the sample size was small, a matched-pair analysis between both groups to non-MDRO colonized control cohorts (2:1 matching) was performed. At 12 months, the MDRO group who did not have an FMT had significantly lower survival (36.4% <jats:italic>versus</jats:italic> 61.9% respectively, <jats:italic>p</jats:italic>=0.012), and higher non relapse mortality (NRM; 60.2% <jats:italic>versus</jats:italic> 16.7% respectively, <jats:italic>p</jats:italic>=0.009) than their paired non-MDRO-colonized cohort. Conversely, there was no difference in survival (70% <jats:italic>versus</jats:italic> 43.4%, <jats:ita
AU - Innes,AJ
AU - Mullish,BH
AU - Ghani,R
AU - Szydlo,RM
AU - Apperley,JF
AU - Olavarria,E
AU - Palanicawandar,R
AU - Kanfer,EJ
AU - Milojkovic,D
AU - McDonald,JAK
AU - Brannigan,ET
AU - Thursz,MR
AU - Williams,HRT
AU - Davies,FJ
AU - Marchesi,JR
AU - Pavl,J
DO - 10.3389/fcimb.2021.684659
PY - 2021///
TI - Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation
T2 - Frontiers in Cellular and Infection Microbiology
UR - http://dx.doi.org/10.3389/fcimb.2021.684659
UR - http://hdl.handle.net/10044/1/91049
VL - 11
ER -